Pentoxifylline to boost liver regrowth after right‑lobe donor hepatectomy
Effect of Pentoxifylline on Liver Regeneration After Right Lobe Donor Hepatectomy: A Randomized Control Trial
This will try giving pentoxifylline to live liver donors having right‑lobe hepatectomy to see if the remaining liver grows faster and lowers the risk of post‑surgery liver problems.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Sponsor | Institute of Liver and Biliary Sciences, India Academic / other |
| Locations | 1 site (New Delhi) |
| Trial ID | NCT07085806 on ClinicalTrials.gov |
What this trial studies
This is a randomized, controlled interventional trial at a single tertiary liver center comparing injection pentoxifylline with a control (Plasmalyte) in live donors undergoing right‑lobe hepatectomy. The drug is given perioperatively and donors are followed with clinical exams, blood tests of liver function, and imaging to track liver volume and recovery. The main aim is to determine whether pentoxifylline improves markers of liver regeneration and reduces posthepatectomy liver dysfunction. Eligible participants are consenting live donors without hypersensitivity to pentoxifylline.
Who should consider this trial
Good fit: Healthy live liver donors scheduled for right‑lobe donor hepatectomy who provide informed consent and have no known hypersensitivity to pentoxifylline are the intended participants.
Not a fit: People who decline consent or who have hypersensitivity to pentoxifylline (or who are not undergoing right‑lobe donor hepatectomy) would not be eligible and therefore would not receive potential benefit from this intervention.
Why it matters
Potential benefit: If successful, pentoxifylline could speed liver regrowth and reduce the risk of posthepatectomy liver failure in live donors, improving donor safety.
How similar studies have performed: Prior randomized trials in non‑cirrhotic patients and animal studies have reported beneficial effects of pentoxifylline on small remnant liver regeneration and protection from small‑for‑size syndrome.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All live donors undergoing Right Donor Hepatectomy after ethical board clearance in the Department of HPB Surgery and Liver Transplantation Exclusion Criteria: * Negative consent Hypersensitivity to Pentoxifylline
Where this trial is running
New Delhi
- Institute of Liver and Biliary Sciences — New Delhi, India (Recruiting)
Study contacts
- Study coordinator: Parneet Dr
- Email: parneet.sunam@gmail.com
- Phone: +917888524169
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.